Novel agents in relapsed/refractory diffuse large B-cell lymphoma

Gaurav Varma; Jordan Goldstein; Ranjana H Advani

doi:10.1002/hon.3143

Novel agents in relapsed/refractory diffuse large B-cell lymphoma

Hematol Oncol. 2023 Jun:41 Suppl 1:92-106. doi: 10.1002/hon.3143.

Authors

Gaurav Varma¹, Jordan Goldstein², Ranjana H Advani²

Affiliations

¹ Division of Hematology and Medical Oncology, Department of Medicine, New York University Grossman School of Medicine, New York, New York, USA.
² Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.

PMID: 37294966
DOI: 10.1002/hon.3143

Abstract

Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), ineligible for or relapsing after autologous stem-cell transplant or chimeric antigen-receptor T-cell therapies have poor outcomes. Several novel agents, polatuzumab vedotin, tafasitamab, loncastuximab tesirine, and selinexor, have been approved and offer new opportunities for this difficult to treat population. Studies are evaluating combination of these agents with chemotherapy and other emerging therapies. Additionally, advances in our understanding of DLBCL biology, genetics, and immune microenvironment have allowed for the identification of new therapeutic targets like Ikaros and Aiolos, IRAK4, MALT1, and CD47 with several agents in ongoing clinical trials. In this chapter we review updated data supporting the use of the approved agents and discuss other emerging novel therapies for patients with R/R DLBCL.

Keywords: DLBCL; novel agents; relapsed/refractory.

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Humans
Immunoconjugates* / therapeutic use
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Lymphoma, Large B-Cell, Diffuse* / etiology
Lymphoma, Non-Hodgkin* / drug therapy
Neoplasm Recurrence, Local / drug therapy
Tumor Microenvironment

Substances

Immunoconjugates